- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dr Reddy's Gets CDSCO Panel Nod to Manufacture, Market Anticancer Drug Lenalidomide Capsules
New Delhi: In a significant development, the drug major Dr. Reddy's Laboratories has got a green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to manufacture and market the anticancer drug Lenalidomide Capsules 25 mg for the proposed indication, “For the treatment of patients with transfusion-dependent anaemia due to low or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities and in combination with Dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy”.
This came after the firm presented the proposal for manufacturing and marketing permission of Lenalidomide Capsule 25mg (using Lenalidomide povidone premix) along with the results of the bioequivalence (BE) study before the committee.
Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow produce normal blood cells and killing abnormal cells in the bone marrow.
Lenalidomide acts by a novel drug mechanism—modulation of the substrate specificity of the CRL4CRBN E3 ubiquitin ligase. In multiple myeloma, lenalidomide induces the ubiquitination of IKZF1 and IKZF3 by CRL4CRBN. Subsequent proteasomal degradation of these transcription factors kills multiple myeloma cells.
Lenalidomide works by stopping cancer cells from developing and stopping blood vessels from growing in the cancer.
At the recent SEC meeting for Oncology and Hematology held on 11 May 2023, the expert panel reviewed the proposal presented by drug major Dr. Reddy's Laboratories for manufacturing and marketing Lenalidomide Capsule 25mg (using Lenalidomide povidone premix) along with the results of the BE study before the committee.
After detailed deliberation, the committee recommended the grant of permission for the manufacturing and marketing of Lenalidomide capsule 25mg (using Lenalidomide povidone premix) for the proposed indication as under:
“For the treatment of patients with transfusion-dependent anaemia due to low or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities and in combination with Dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy”
Also Read:Justify rationality for FDC Sitagliptin, Lobeglitazon: CDSCO Panel Tells Synokem Pharma
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.